EPO Patent Application EP4522154A1: BCL-XL/BCL-2 Degraders

ChangeBridge: EPO Bulletin - Pharma (A61K)

Published March 18th, 2026

Detected March 25th, 2026

Summary

The European Patent Office has published patent application EP4522154A1 by Kymera Therapeutics, Inc. The application details BCL-XL/BCL-2 degraders and their uses. This publication is part of the standard patent application process.

View original document View source feed page

What changed

The European Patent Office (EPO) has published patent application EP4522154A1, filed by Kymera Therapeutics, Inc. The application, titled "BCL-XL/BCL-2 Degraders and Uses Thereof," outlines novel compounds and their therapeutic applications, specifically targeting BCL-XL and BCL-2 proteins. This publication signifies a step in the patent examination process.

This patent application does not impose new regulatory obligations or compliance requirements on regulated entities. It is an informational notice regarding intellectual property protection for pharmaceutical innovations. Compliance officers should note this publication as part of the landscape of drug development and patent filings in the pharmaceutical sector.

Source document (simplified)

← EPO Patent Bulletin

BCL-XL/BCL-2 DEGRADERS AND USES THEREOF

Publication EP4522154A1 Kind: A1 Mar 18, 2026

Applicants

Kymera Therapeutics, Inc.

Inventors

DONG, Huijun, YANG, Bin, PENNINGTON, Lewis Dale, COMER, Eamon, FORD, Melissa, AVERSA, Robert, WEISS, Matthew M., ZHU, Xiao, BEUMING, Thijs

IPC Classifications

A61K 31/395 20060101AFI20231117BHEP A61K 31/16 20060101ALI20231117BHEP A61K 31/18 20060101ALI20231117BHEP A61K 31/33 20060101ALI20231117BHEP

Designated States

AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

View original document →